{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T13:02:30Z","timestamp":1794402150103,"version":"4.9.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["2017NOVPCC1066"],"award-info":[{"award-number":["2017NOVPCC1066"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C10604\/A25151"],"award-info":[{"award-number":["C10604\/A25151"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Preclinical models that can accurately predict outcomes in the clinic are much sought after in the field of cancer drug discovery and development. Existing models such as organoids and patient-derived xenografts have many advantages, but they suffer from the drawback of not contextually preserving human tumour architecture. This is a particular problem for the preclinical testing of immunotherapies, as these agents require an intact tumour human-specific microenvironment for them to be effective. In this review, we explore the potential of patient-derived explants (PDEs) for fulfilling this need. PDEs involve the ex vivo culture of fragments of freshly resected human tumours that retain the histological features of original tumours. PDE methodology for anti-cancer drug testing has been in existence for many years, but the platform has not been widely adopted in translational research facilities, despite strong evidence for its clinical predictivity. By modifying PDE endpoint analysis to include the spatial profiling of key biomarkers by using multispectral imaging, we argue that PDEs offer many advantages, including the ability to correlate drug responses with tumour pathology, tumour heterogeneity and changes in the tumour microenvironment. As such, PDEs are a powerful model of choice for cancer drug and biomarker discovery programmes.<\/jats:p>","DOI":"10.1038\/s41416-019-0672-6","type":"journal-article","created":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T19:06:24Z","timestamp":1577905584000},"page":"735-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":225,"title":["Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery"],"prefix":"10.1038","volume":"122","author":[{"given":"Ian R.","family":"Powley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeta","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Howells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kettleborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Bryans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hammonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMc1504317","volume":"372","author":"JA DiMasi","year":"2015","unstructured":"DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. The cost of drug development. N. Engl. J. Med. 372, 1972 (2015).","journal-title":"N. Engl. J. Med."},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","volume":"21","author":"B Seruga","year":"2015","unstructured":"Seruga, B., Ocana, A., Amir, E. & Tannock, I. F. Failures in phase III: causes and consequences. Clin. Cancer Res. 21, 4552\u20134560 (2015).","journal-title":"Clin. Cancer Res."},{"key":"672_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711\u2013715 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1517\/17460441.2013.768984","volume":"8","author":"L Moreno","year":"2013","unstructured":"Moreno, L. & Pearson, A. D. How can attrition rates be reduced in cancer drug discovery? Expert Opin. Drug Discov. 8, 363\u2013368 (2013).","journal-title":"Expert Opin. Drug Discov."},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R. et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat. Rev. Drug Discov. 9, 203\u2013214 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/jnci\/djq463","volume":"103","author":"A Ocana","year":"2011","unstructured":"Ocana, A. & Tannock, I. F. When are \u201cpositive\u201d clinical trials in oncology truly positive? J. Natl Cancer Inst. 103, 16\u201320 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191\u2013200 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-13-1222","volume":"19","author":"A Ocana","year":"2013","unstructured":"Ocana, A., Amir, E., Vera-Badillo, F., Seruga, B. & Tannock, I. F. Phase III trials of targeted anticancer therapies: redesigning the concept. Clin. Cancer Res. 19, 4931\u20134940 (2013).","journal-title":"Clin. Cancer Res."},{"key":"672_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrd1158","volume":"2","author":"B Booth","year":"2003","unstructured":"Booth, B., Glassman, R. & Ma, P. Oncology\u2019s trials. Nat. Rev. Drug Discov. 2, 609\u2013610 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"672_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M., Rowan, A. J., Horswell, S., Math, M., Larkin, J., Endesfelder, D. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"672_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"672_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10873-2","volume":"7","author":"R Kanzaki","year":"2017","unstructured":"Kanzaki, R., Naito, H., Kise, K., Takara, K., Eino, D., Minami, M. et al. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Sci. Rep. 7, 10613 (2017).","journal-title":"Sci. Rep."},{"key":"672_CR13","unstructured":"Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017)."},{"key":"672_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson, B., Li, Y., Lin, Y., Liu, E. T. & Patnaik, A. Mouse models for cancer immunotherapy research. Cancer Discov. 8, 1358\u20131365 (2018).","journal-title":"Cancer Discov."},{"key":"672_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc.2016.91","volume":"16","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Pitt, J. M., Daillere, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 16, 759\u2013773 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41416-018-0353-x","volume":"120","author":"F Bertolini","year":"2019","unstructured":"Bertolini, F. Desperately seeking\u2026models to find the right partner and the best use for checkpoint inhibitors. Br. J. Cancer 120, 139\u2013140 (2019).","journal-title":"Br. J. Cancer"},{"key":"672_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.10.015","volume":"79-80","author":"C Unger","year":"2014","unstructured":"Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschlager, M. & Dolznig, H. Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. Adv. Drug Deliv. Rev. 79\u201380, 50\u201367 (2014).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrc2820","volume":"10","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V., Haber, D. A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241\u2013253 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"672_CR19","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570\u2013575 (2012).","journal-title":"Nature"},{"key":"672_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M., Huang, F. W., Jane-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R. 3rd et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"672_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"672_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"672_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462\u2013477 (2017).","journal-title":"Cancer Discov."},{"key":"672_CR25","doi-asserted-by":"publisher","first-page":"13308","DOI":"10.1073\/pnas.1516689112","volume":"112","author":"F Weeber","year":"2015","unstructured":"Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K. K., Krijgsman, O., Kuilman, T. et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc. Natl Acad. Sci. USA 112, 13308\u201313311 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","volume":"18","author":"M Fujii","year":"2016","unstructured":"Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827\u2013838 (2016).","journal-title":"Cell Stem Cell"},{"key":"672_CR27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"672_CR28","unstructured":"Sontheimer-Phelps, A., Hassell, B. A. & Ingber, D. E. Modelling cancer in microfluidic human organs-on-chips. Nat. Rev. Cancer 19, 65\u201381 (2019)."},{"key":"672_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep38221","volume":"6","author":"G Calibasi Kocal","year":"2016","unstructured":"Calibasi Kocal, G., Guven, S., Foygel, K., Goldman, A., Chen, P., Sengupta, S. et al. Dynamic microenvironment induces phenotypic plasticity of esophageal cancer cells under flow. Sci. Rep. 6, 38221 (2016).","journal-title":"Sci. Rep."},{"key":"672_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nature20168","volume":"539","author":"N Gjorevski","year":"2016","unstructured":"Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M. E., Ordonez-Moran, P. et al. Designer matrices for intestinal stem cell and organoid culture. Nature 539, 560\u2013564 (2016).","journal-title":"Nature"},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"672_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"22","author":"T Seino","year":"2018","unstructured":"Seino, T., Kawasaki, S., Shimokawa, M., Tamagawa, H., Toshimitsu, K., Fujii, M. et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell 22, 454\u2013467 e456 (2018).","journal-title":"Cell Stem Cell"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176\u2013187 (2014).","journal-title":"Cell"},{"key":"672_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386 e310 (2018).","journal-title":"Cell"},{"key":"672_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nm.3853","volume":"21","author":"SE Gould","year":"2015","unstructured":"Gould, S. E., Junttila, M. R. & de Sauvage, F. J. Translational value of mouse models in oncology drug development. Nat. Med. 21, 431\u2013439 (2015).","journal-title":"Nat. Med."},{"key":"672_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrc.2017.92","volume":"17","author":"N Gengenbacher","year":"2017","unstructured":"Gengenbacher, N., Singhal, M. & Augustin, H. G. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat. Rev. Cancer 17, 751\u2013765 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"672_CR37","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","volume":"20","author":"CL Hodgkinson","year":"2014","unstructured":"Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F. et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 20, 897\u2013903 (2014).","journal-title":"Nat. Med."},{"key":"672_CR38","doi-asserted-by":"crossref","unstructured":"Ireson, C. R., Alavijeh, M. S., Palmer, A. M., Fowler, E. R. & Jones, H. J. The role of mouse tumour models in the discovery and development of anticancer drugs. Br. J. Cancer 121, 101\u2013108 (2019).","DOI":"10.1038\/s41416-019-0495-5"},{"key":"672_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov"},{"key":"672_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338\u2013350 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"672_CR41","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","volume":"17","author":"YS DeRose","year":"2011","unstructured":"DeRose, Y. S., Wang, G., Lin, Y. C., Bernard, P. S., Buys, S. S., Ebbert, M. T. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514\u20131520 (2011).","journal-title":"Nat. Med."},{"key":"672_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","volume":"518","author":"P Eirew","year":"2015","unstructured":"Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422\u2013426 (2015).","journal-title":"Nature"},{"key":"672_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","volume":"167","author":"A Bruna","year":"2016","unstructured":"Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N. et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167, 260\u2013274 e222 (2016).","journal-title":"Cell"},{"key":"672_CR44","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","volume":"10","author":"M Hidalgo","year":"2011","unstructured":"Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311\u20131316 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"672_CR45","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko, E., Paz, K., Ciznadija, D., Sloma, I., Katz, A., Vasquez-Dunddel, D. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595\u20132605 (2017).","journal-title":"Ann. Oncol."},{"key":"672_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","volume":"10","author":"Y Lai","year":"2017","unstructured":"Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L. & Li, P. Current status and perspectives of patient-derived xenograft models in cancer research. J. Hematol. Oncol. 10, 106 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"672_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/cmi.2012.6","volume":"9","author":"AC Drake","year":"2012","unstructured":"Drake, A. C., Chen, Q. & Chen, J. Engineering humanized mice for improved hematopoietic reconstitution. Cell. Mol. Immunol. 9, 215\u2013224 (2012).","journal-title":"Cell. Mol. Immunol."},{"key":"672_CR48","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","volume":"32","author":"M Wang","year":"2018","unstructured":"Wang, M., Yao, L. C., Cheng, M., Cai, D., Martinek, J., Pan, C. X. et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 32, 1537\u20131549 (2018).","journal-title":"FASEB J"},{"key":"672_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","volume":"157","author":"MA King","year":"2009","unstructured":"King, M. A., Covassin, L., Brehm, M. A., Racki, W., Pearson, T., Leif, J. et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 157, 104\u2013118 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"672_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/iid3.124","volume":"4","author":"S Jangalwe","year":"2016","unstructured":"Jangalwe, S., Shultz, L. D., Mathew, A. & Brehm, M. A. Improved B cell development in humanized NOD-scid IL2Rgamma(null) mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3. Immun. Inflamm. Dis. 4, 427\u2013440 (2016).","journal-title":"Immun. Inflamm. Dis."},{"key":"672_CR51","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood-2015-10-676452","volume":"128","author":"Y Saito","year":"2016","unstructured":"Saito, Y., Ellegast, J. M., Rafiei, A., Song, Y., Kull, D., Heikenwalder, M. et al. Peripheral blood CD34(+) cells efficiently engraft human cytokine knock-in mice. Blood 128, 1829\u20131833 (2016).","journal-title":"Blood"},{"key":"672_CR52","first-page":"545","volume":"12","author":"J Leighton","year":"1951","unstructured":"Leighton, J. A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. J. Natl Cancer Inst. 12, 545\u2013561 (1951).","journal-title":"J. Natl Cancer Inst."},{"key":"672_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-7745-1_2","volume":"1760","author":"RM Hoffman","year":"2018","unstructured":"Hoffman, R. M. 3D sponge-matrix histoculture: an overview. Methods Mol. Biol. 1760, 11\u201317 (2018).","journal-title":"Methods Mol. Biol."},{"key":"672_CR54","first-page":"275","volume":"15","author":"J Leighton","year":"1954","unstructured":"Leighton, J. The growth patterns of some transplantable animal tumors in sponge matrix tissue culture. J. Natl Cancer Inst. 15, 275\u2013293 (1954).","journal-title":"J. Natl Cancer Inst."},{"key":"672_CR55","first-page":"359","volume":"17","author":"J Leighton","year":"1957","unstructured":"Leighton, J., Kline, I., Belkin, M., Legallais, F. & Orr, H. C. The similarity in histologic appearance of some human cancer and normal cell strains in sponge-matrix tissue culture. Cancer Res. 17, 359\u2013363 (1957).","journal-title":"Cancer Res."},{"key":"672_CR56","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1073\/pnas.83.8.2694","volume":"83","author":"AE Freeman","year":"1986","unstructured":"Freeman, A. E. & Hoffman, R. M. In vivo-like growth of human tumors in vitro. Proc. Natl Acad. Sci. USA 83, 2694\u20132698 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR57","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1073\/pnas.84.14.5029","volume":"84","author":"RA Vescio","year":"1987","unstructured":"Vescio, R. A., Redfern, C. H., Nelson, T. J., Ugoretz, S., Stern, P. H. & Hoffman, R. M. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl Acad. Sci. USA 84, 5029\u20135033 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR58","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1073\/pnas.88.12.5163","volume":"88","author":"RA Vescio","year":"1991","unstructured":"Vescio, R. A., Connors, K. M., Kubota, T. & Hoffman, R. M. Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc. Natl Acad. Sci. USA 88, 5163\u20135166 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR59","first-page":"305","volume":"1","author":"T Furukawa","year":"1995","unstructured":"Furukawa, T., Kubota, T. & Hoffman, R. M. Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1, 305\u2013311 (1995).","journal-title":"Clin. Cancer Res."},{"key":"672_CR60","first-page":"231","volume":"30","author":"T Yoshimasu","year":"2003","unstructured":"Yoshimasu, T., Oura, S., Hirai, I., Kokawa, Y., Sasaki, R., Honda, K. et al. Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer. Gan To Kagaku Ryoho 30, 231\u2013235 (2003).","journal-title":"Gan To Kagaku Ryoho"},{"key":"672_CR61","unstructured":"Yoshimasu, T., Oura, S., Hirai, I., Kokawa, Y., Hata, K., Kawago, M. et al. Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer. Gan To Kagaku Ryoho 32, 1013\u20131016 (2005)."},{"key":"672_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jtcvs.2006.06.030","volume":"133","author":"T Yoshimasu","year":"2007","unstructured":"Yoshimasu, T., Oura, S., Hirai, I., Tamaki, T., Kokawa, Y., Hata, K. et al. Data acquisition for the histoculture drug response assay in lung cancer. J. Thorac. Cardiovasc. Surg. 133, 303\u2013308 (2007).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"672_CR63","first-page":"26","volume":"61","author":"M Tanahashi","year":"2008","unstructured":"Tanahashi, M., Yamada, T., Moriyama, S., Suzuki, E. & Niwa, H. The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer. Kyobu Geka 61, 26\u201330 (2008).","journal-title":"Kyobu Geka"},{"key":"672_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2169\/internalmedicine.48.1659","volume":"48","author":"Y Hayashi","year":"2009","unstructured":"Hayashi, Y., Kuriyama, H., Umezu, H., Tanaka, J., Yoshimasu, T., Furukawa, T. et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern. Med. 48, 203\u2013208 (2009).","journal-title":"Intern. Med."},{"key":"672_CR65","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrurol.2013.126","volume":"10","author":"MM Centenera","year":"2013","unstructured":"Centenera, M. M., Raj, G. V., Knudsen, K. E., Tilley, W. D. & Butler, L. M. Ex vivo culture of human prostate tissue and drug development. Nat. Rev. Urol. 10, 483\u2013487 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"672_CR66","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1158\/1078-0432.CCR-12-0782","volume":"18","author":"MM Centenera","year":"2012","unstructured":"Centenera, M. M., Gillis, J. L., Hanson, A. R., Jindal, S., Taylor, R. A., Risbridger, G. P. et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin. Cancer Res. 18, 3562\u20133570 (2012).","journal-title":"Clin. Cancer Res."},{"key":"672_CR67","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4161\/cc.21195","volume":"11","author":"JL Dean","year":"2012","unstructured":"Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K. et al. Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11, 2756\u20132761 (2012).","journal-title":"Cell Cycle"},{"key":"672_CR68","first-page":"1765","volume":"26","author":"F Pirnia","year":"2006","unstructured":"Pirnia, F., Frese, S., Gloor, B., Hotz, M. A., Luethi, A., Gugger, M. et al. Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer Res. 26, 1765\u20131772 (2006).","journal-title":"Anticancer Res."},{"key":"672_CR69","first-page":"153303381876449","volume":"17","author":"GC Mariel","year":"2018","unstructured":"Mariel, G. C., Edith, C. I., Pilar, C. R., Elena, G. N., Humberto, R. M., Guadalupe, M. M. et al. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. Technol. Cancer Res. Treat. 17, 1533033818764499 (2018).","journal-title":"Technol. Cancer Res. Treat."},{"key":"672_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/labinvest.2013.141","volume":"94","author":"SL Maund","year":"2014","unstructured":"Maund, S. L., Nolley, R. & Peehl, D. M. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Lab. Invest. 94, 208\u2013221 (2014).","journal-title":"Lab. Invest."},{"key":"672_CR71","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11748-008-0332-x","volume":"57","author":"T Yoshimasu","year":"2009","unstructured":"Yoshimasu, T., Ohta, F., Oura, S., Tamaki, T., Shimizu, Y., Naito, K. et al. Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen. Thorac. Cardiovasc. Surg. 57, 138\u2013143 (2009).","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"672_CR72","first-page":"1373","volume":"12","author":"D Colangelo","year":"1992","unstructured":"Colangelo, D., Guo, H. Y., Connors, K. M., Kubota, T., Silvestro, L. & Hoffman, R. M. Correlation of drug response in human tumors histocultured in vitro with an image-analysis MTT end point and in vivo xenografted in nude mice. Anticancer Res. 12, 1373\u20131376 (1992).","journal-title":"Anticancer Res"},{"key":"672_CR73","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl Acad. Sci. USA 107, 8352\u20138356 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"672_CR74","first-page":"6915","volume":"14","author":"B Wei","year":"2017","unstructured":"Wei, B., Wang, J., Zhang, X., Qian, Z., Wu, J., Sun, Y. et al. Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. Oncol. Lett. 14, 6915\u20136922 (2017).","journal-title":"Oncol. Lett."},{"key":"672_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7169","volume":"6","author":"B Majumder","year":"2015","unstructured":"Majumder, B., Baraneedharan, U., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6, 6169 (2015).","journal-title":"Nat. Commun."},{"key":"672_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7139","volume":"6","author":"A Goldman","year":"2015","unstructured":"Goldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M. et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat. Commun. 6, 6139 (2015).","journal-title":"Nat. Commun."},{"key":"672_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13402-016-0311-7","volume":"40","author":"S Bhattacharyya","year":"2017","unstructured":"Bhattacharyya, S., Sekar, V., Majumder, B., Mehrotra, D. G., Banerjee, S., Bhowmick, A. K. et al. CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer. Cell Oncol. 40, 145\u2013155 (2017).","journal-title":"Cell Oncol."},{"key":"672_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01566-x","volume":"7","author":"N Brijwani","year":"2017","unstructured":"Brijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M. et al. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci. Rep. 7, 1502 (2017).","journal-title":"Sci. Rep."},{"key":"672_CR79","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/0008-5472.CAN-16-1121","volume":"77","author":"E Karekla","year":"2017","unstructured":"Karekla, E., Liao, W. J., Sharp, B., Pugh, J., Reid, H., Quesne, J. L. et al. Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Res. 77, 2029\u20132039 (2017).","journal-title":"Cancer Res."},{"key":"672_CR80","doi-asserted-by":"crossref","unstructured":"Twiddy, D., Naik, S., Mistry, R., Edwards, J., Walker, R. A., Cohen, G. M. et al. A TRAILR 1-specific ligand in combination with doxorubin selectively targets primary breast tumour cells for apoptosis. Breast Cancer Res. 12, 17\u201318 (2010).","DOI":"10.1186\/bcr2555"},{"key":"672_CR81","doi-asserted-by":"publisher","first-page":"298ra117","DOI":"10.1126\/scitranslmed.aaa7619","volume":"7","author":"H Cai","year":"2015","unstructured":"Cai, H., Scott, E., Kholghi, A., Andreadi, C., Rufini, A., Karmokar, A. et al. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci. Transl. Med. 7, 298ra117 (2015).","journal-title":"Sci. Transl. Med."},{"key":"672_CR82","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/onc.2015.213","volume":"35","author":"S Busacca","year":"2016","unstructured":"Busacca, S., Law, E. W., Powley, I. R., Proia, D. A., Sequeira, M., Le Quesne, J. et al. Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene 35, 1483\u20131492 (2016).","journal-title":"Oncogene"},{"key":"672_CR83","doi-asserted-by":"crossref","unstructured":"Kolluri, K. K., Alifrangis, C., Kumar, N., Ishii, Y., Price, S., Michaut, M. et al. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife 7, e30224 (2018).","DOI":"10.7554\/eLife.30224"},{"key":"672_CR84","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1200\/JCO.2007.13.1011","volume":"25","author":"MJ Dyer","year":"2007","unstructured":"Dyer, M. J., MacFarlane, M. & Cohen, G. M. Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol. 25, 4505\u20134506 (2007).","journal-title":"J. Clin. Oncol."},{"key":"672_CR85","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/1878-0261.12354","volume":"12","author":"MM Centenera","year":"2018","unstructured":"Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H. et al. A patient-derived explant (PDE) model of hormone-dependent cancer. Mol. Oncol. 12, 1608\u20131622 (2018).","journal-title":"Mol. Oncol."},{"key":"672_CR86","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L. et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2, 1134\u20131149 (2012).","journal-title":"Cancer Discov."},{"key":"672_CR87","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A. et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature 523, 313\u2013317 (2015).","journal-title":"Nature"},{"key":"672_CR88","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1074\/mcp.RA118.000633","volume":"17","author":"EV Nguyen","year":"2018","unstructured":"Nguyen, E. V., Centenera, M. M., Moldovan, M., Das, R., Irani, S., Vincent, A. D. et al. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants. Mol. Cell. Proteomics 17, 1470\u20131486 (2018).","journal-title":"Mol. Cell. Proteomics"},{"key":"672_CR89","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euo.2018.04.019","volume":"1","author":"AA Shafi","year":"2018","unstructured":"Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., McCue, P. A., Shah, N. et al. Patient-derived models reveal impact of the tumor microenvironment on therapeutic response. Eur. Urol. Oncol. 1, 325\u2013337 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"672_CR90","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0022-1759(89)90104-X","volume":"125","author":"MN Bobrow","year":"1989","unstructured":"Bobrow, M. N., Harris, T. D., Shaughnessy, K. J. & Litt, G. J. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods 125, 279\u2013285 (1989).","journal-title":"J. Immunol. Methods"},{"key":"672_CR91","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1177\/44.12.8985127","volume":"44","author":"B Hunyady","year":"1996","unstructured":"Hunyady, B., Krempels, K., Harta, G. & Mezey, E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J. Histochem. Cytochem. 44, 1353\u20131362 (1996).","journal-title":"J. Histochem. Cytochem."},{"key":"672_CR92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymeth.2014.08.016","volume":"70","author":"EC Stack","year":"2014","unstructured":"Stack, E. C., Wang, C., Roman, K. A. & Hoyt, C. C. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46\u201358 (2014).","journal-title":"Methods"},{"key":"672_CR93","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1369\/jhc.6A7134.2007","volume":"55","author":"ZE Toth","year":"2007","unstructured":"Toth, Z. E. & Mezey, E. Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J. Histochem. Cytochem. 55, 545\u2013554 (2007).","journal-title":"J. Histochem. Cytochem."},{"key":"672_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13942-8","volume":"7","author":"ER Parra","year":"2017","unstructured":"Parra, E. R., Uraoka, N., Jiang, M., Cook, P., Gibbons, D., Forget, M. A. et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci. Rep. 7, 13380 (2017).","journal-title":"Sci. Rep."},{"key":"672_CR95","doi-asserted-by":"crossref","first-page":"79793","DOI":"10.18632\/oncotarget.19558","volume":"8","author":"IJ Park","year":"2017","unstructured":"Park, I. J., An, S., Kim, S. Y., Lim, H. M., Hong, S. M., Kim, M. J. et al. Prediction of radio-responsiveness with immune-profiling in patients with rectal cancer. Oncotarget 8, 79793\u201379802 (2017).","journal-title":"Oncotarget"},{"key":"672_CR96","doi-asserted-by":"crossref","unstructured":"Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C. A., Hirsch, D., Bankhead, P. et al. Topography of cancer-associated immune cells in human solid tumors. eLife 7, e36967 (2018).","DOI":"10.7554\/eLife.36967"},{"key":"672_CR97","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1007\/s00216-017-0443-2","volume":"409","author":"IS Sorensen","year":"2017","unstructured":"Sorensen, I. S., Janfelt, C., Nielsen, M. M. B., Mortensen, R. W., Knudsen, N. O., Eriksson, A. H. et al. Combination of MALDI-MSI and cassette dosing for evaluation of drug distribution in human skin explant. Anal. Bioanal. Chem. 409, 4993\u20135005 (2017).","journal-title":"Anal. Bioanal. Chem."},{"key":"672_CR98","doi-asserted-by":"publisher","first-page":"e0144162","DOI":"10.1371\/journal.pone.0144162","volume":"10","author":"E Oh","year":"2015","unstructured":"Oh, E., Choi, Y. L., Kwon, M. J., Kim, R. N., Kim, Y. J., Song, J. Y. et al. Comparison of accuracy of whole-exome sequencing with formalin-fixed paraffin-embedded and fresh frozen tissue samples. PLoS ONE 10, e0144162 (2015).","journal-title":"PLoS One"},{"key":"672_CR99","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/gim.2017.241","volume":"20","author":"P Robbe","year":"2018","unstructured":"Robbe, P., Popitsch, N., Knight, S. J. L., Antoniou, P., Becq, J., He, M. et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. Genet. Med. 20, 1196\u20131205 (2018).","journal-title":"Genet. Med."},{"key":"672_CR100","doi-asserted-by":"publisher","first-page":"1481,1483","DOI":"10.1126\/science.278.5342.1481","volume":"278","author":"RF Bonner","year":"1997","unstructured":"Bonner, R. F., Emmert-Buck, M., Cole, K., Pohida, T., Chuaqui, R., Goldstein, S. et al. Laser capture microdissection: molecular analysis of tissue. Science 278, 1481\u20131483 (1997).","journal-title":"Science"},{"key":"672_CR101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-61779-055-3_7","volume":"724","author":"R Burgemeister","year":"2011","unstructured":"Burgemeister, R. Laser capture microdissection of FFPE tissue sections bridging the gap between microscopy and molecular analysis. Methods Mol. Biol. 724, 105\u2013115 (2011).","journal-title":"Methods Mol. Biol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0672-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:06:22Z","timestamp":1684602382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0672-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3,17]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0672-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All work with patient samples was performed with full ethical approval provided by the University of Leicester Research Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was supported and funded by the Explant Consortium comprising four partners: The University of Leicester, The MRC Toxicology Unit, Cancer Research UK Therapeutic Discovery Laboratories and LifeArc. Additional support was provided by the CRUK-NIHR Leicester Experimental Cancer Medicine Centre (C10604\/A25151). Funding for Gareth Miles was provided by Breast Cancer Now\u2019s Catalyst Programme (2017NOVPCC1066), which is supported by funding from Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}